Evaluate Safety, Whole-Body Distribution & Radiation Dosimetry in

See also
Status	Clinical Trial	Phase
Completed	`NCT04400656` - PROState Pathway Embedded Comparative Trial
Completed	`NCT03554317` - COMbination of Bipolar Androgen Therapy and Nivolumab	Phase 2
Recruiting	`NCT04533958` - Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy	N/A
Not yet recruiting	`NCT06009549` - A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients
Withdrawn	`NCT05771896` - Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC	Phase 3
Completed	`NCT01981122` - A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer	Phase 2
Completed	`NCT01233557` - Biomarkers of Bone Resorption in Metastatic Prostate Cancer	N/A
Completed	`NCT01012141` - Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer	Phase 2
Recruiting	`NCT04067713` - Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer
Active, not recruiting	`NCT04332744` - Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)	Phase 2
Completed	`NCT04545697` - mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer	N/A
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Not yet recruiting	`NCT04031378` - Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer	Phase 2
Completed	`NCT02278055` - Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer	Phase 2
Completed	`NCT04193657` - Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC
Completed	`NCT02260817` - Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer	Phase 3
Terminated	`NCT00216060` - Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy	Phase 3
Recruiting	`NCT04070209` - Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)	Phase 2
Recruiting	`NCT04925648` - Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction	Phase 2
Completed	`NCT01303705` - Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer	Phase 1

NCT number	NCT06359821
Study type	Interventional
Source	Sichuan University
Contact
Status	Enrolling by invitation
Phase	Early Phase 1
Start date	May 17, 2024
Completion date	April 15, 2026

Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms